Journal profile · Oncology
Neoplasma
ISSN 0028-2685 · eISSN 1338-4317 · Vydavatel'stvo Slovenkej Akademie Vied/Veda Publishing House of the Slovak Academy of Sciences · SLOVAKIA · Bimonthly · Founded 1957
Neoplasma: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.43; subscription journal; median 122 days to acceptance (92 articles, last 24 months); community-reported acceptance: about 75%; 50 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Neoplasma is published by Vydavatel'stvo Slovenkej Akademie Vied/Veda Publishing House of the Slovak Academy of Sciences and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Cancer-related molecular mechanisms research, MicroRNA in disease regulation and RNA modifications and cancer, together about 30.2% of its articles. Its main subfields are Molecular Biology and Cancer Research. (generated from OpenAlex topic counts and CAS ranking data)
The journal Neoplasma publishes articles on experimental and clinical oncology and cancer epidemiology.
Source: LetPub
Research area (LetPub): Oncology
Editor-in-chief Ján SedlákPublisher website
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer-related molecular mechanisms researchBiochemistry, Genetics and Molecular Biology11.4%
- MicroRNA in disease regulationBiochemistry, Genetics and Molecular Biology10.4%
- RNA modifications and cancerBiochemistry, Genetics and Molecular Biology8.4%
- Circular RNAs in diseasesBiochemistry, Genetics and Molecular Biology8.1%
- Cancer Cells and MetastasisMedicine4.7%
- Cancer, Hypoxia, and MetabolismBiochemistry, Genetics and Molecular Biology4.7%
- Epigenetics and DNA MethylationBiochemistry, Genetics and Molecular Biology4.7%
- Lung Cancer Treatments and MutationsMedicine3.9%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.43LetPub ·
- CiteScore 2026-06
- 4.8LetPub ·
- SJR 2026-06
- 0.59LetPub ·
- SNIP 2026-06
- 0.36LetPub ·
- h-index
- 43LetPub ·
- h-index
- 58OpenAlex ·
- i10-index
- 995OpenAlex ·
- 2-year mean citedness
- 2.22OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 4.14%LetPub ·
Volume
- Articles per year
- 42LetPub ·
Articles by year OpenAlex count · 1,799 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 36 | 15 | 4 |
| 2025 | 50 | 48 | 49 |
| 2024 | 54 | 54 | 258 |
| 2023 | 67 | 67 | 454 |
| 2022 | 122 | 109 | 1,102 |
| 2021 | 132 | 127 | 1,366 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
122 daysMedian, submission to acceptance · P25–P75 88 days – 164 days
- Acceptance to online
- median 16 days (49 articles)
- Submission to online
- median 133 days
- Sample
- 92 articles with submission and acceptance dates (86 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 3 monthsLetPub ·
- Average acceptance (community reports)
- 75%LetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Subscription journalLetPub
A subscription journal: articles are read by subscription or purchase, and authors usually pay no publication charge.
No source has fee information yet; check the journal's website.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Policy excerpts from the journal's websiteLicense & copyright
- License & copyright
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP. Model summary
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Vydavatel'stvo Slovenkej Akademie Vied/Veda Publishing House of the Slovak Academy of Sciences
- Country or region
- SLOVAKIA
- Language
- English
- Frequency
- Bimonthly
- Founded
- 1957
- ISSN
- 0028-2685
- Electronic ISSN
- 1338-4317
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about Neoplasma
What CAS zone is Neoplasma in?
In the 2025 upgraded edition of the CAS Journal Ranking, Neoplasma is in Zone 4 of Medicine, and in Zone 4 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Neoplasma?
The latest impact factor listed by LetPub is 2.43; CiteScore 4.8, h-index 58.
How long does peer review take at Neoplasma?
Based on the dates recorded on 92 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 122 days (interquartile range 88–164 days); authors report an average review time of about 3 months; the community-reported acceptance is “about 75%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Neoplasma?
According to LetPub and DOAJ records, Neoplasma is indexed in SCIE and Scopus.
Is Neoplasma open access, and what is the APC?
Neoplasma is a subscription journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .